Aqualyx

Aqualyx is a Marllor Biomedical product family built around a deoxycholate-derived solution for localized body-contouring use. Its present commercial identity requires care: Marllor currently calls the core product Aqualyx Cosmetic, while older and current professional-facing material describes transdermal delivery, adipose-cell lysis, and treatment areas. Those statements do not by themselves establish the product’s legal classification or authorization for injection in a particular country.

Quick reference

Field	Aqualyx
Current brand presentation	Aqualyx Cosmetic; Aqualyx Face is a related kit
Declared material family	Deoxycholate-derived formulation
Manufacturer-described formula	Phosphatidylcholine-free microgelatinous solution containing a weakened sodium-deoxycholate system, buffer components, galactose derivatives, water, and sodium chloride
Historical brochure presentation	10 vials, 8 mL per vial
Current regulatory identity	Must be verified market by market; a current regulator-issued authorization and current IFU were not established from the reviewed public material
United States status	Not FDA approved as a fat-dissolving injection
Company context	Marllor Biomedical presents itself as trademark owner and guarantor of production and distribution
Authenticity issue	Marllor warns of counterfeit Aqualyx and Aqualyx Face products and uses package QR verification

The formulation and package statements come from a Marllor professional brochure, while the current naming and authenticity statements come from Marllor’s live product pages (Marllor professional brochure 🔗; Aqualyx Cosmetic 🔗; Aqualyx Face 🔗). They are manufacturer claims, not independent confirmation of composition, sterility, clinical performance, or authorization.

Formulation identity

Marllor’s brochure describes Aqualyx as phosphatidylcholine-free and identifies a weakened sodium-deoxycholate detergent system as the principal agent associated with adipose-cell disruption. The brochure lists the sodium salt of (3α, 5β, 12α)-3,12-dihydroxy-5-cholan-24-oic acid, a buffer system, D-galactose, 3,6-anhydro-L-galactose, water, and sodium chloride.

This is more specific than calling Aqualyx simply a “deoxycholic-acid injection,” but important finished-product details remain unavailable in the reviewed public material:

• quantitative concentration for each component
• a current lot-linked certificate of analysis
• a current regulator-hosted label or IFU
• independently verified sterility and manufacturing information
• evidence that the same formula and presentation apply in every market

The absence of phosphatidylcholine in the manufacturer-described formula distinguishes Aqualyx from PPC/deoxycholate mixtures such as some products marketed under the Lipo Lab name. Shared use of a deoxycholate-related ingredient does not establish equivalent concentration, excipients, tissue behavior, or safety.

Current presentation and classification boundary

Marllor’s current website consistently labels the core product Aqualyx Cosmetic and describes it as a body-contouring treatment. The same site calls Aqualyx a compound from the deoxycholate family. A separate Aqualyx Face kit is presented for the double-chin area and includes Seralyx, a serum with additional declared components (Marllor Aqualyx Cosmetic 🔗; Marllor Aqualyx Face 🔗).

The word cosmetic is part of the current commercial presentation. It should not be silently replaced with medicine, medical device, or approved injectable. Conversely, professional-facing descriptions of adipose-cell lysis should not be used to infer that an externally applied cosmetic has authorization for injection.

Classification is not an injection authorization

A trademark category, a manufacturer’s website category, ISO or GMP language, a CE-related claim, and a national authorization are different records. Before clinical interpretation, verify the exact product, intended route, legal classification, conformity or authorization number, certificate validity, economic operator, and local market.

United States status

The FDA names Aqualyx among fat-dissolving injections marketed online that are not FDA approved. In the same safety communication, the agency states that Kybella is the only FDA-approved fat-dissolving injectable drug and that its approval is limited to reducing fat under the chin in adults (FDA safety communication 🔗).

This is a US regulatory statement. It does not prove that Aqualyx is prohibited in every country, nor does availability in another country establish an FDA approval.

Counterfeit and traceability issue

Marllor states that counterfeit products circulate under both the Aqualyx Cosmetic and Aqualyx Face names. It identifies itself as the trademark owner and guarantor of production and distribution and says that current packages carry a secure QR code; according to Marllor, absence of that code indicates a counterfeit product (Aqualyx Cosmetic authenticity notice 🔗; Aqualyx Face authenticity notice 🔗).

That brand-authentication system is useful for traceability, but a valid QR code would not answer every clinical or regulatory question. Product identity review should also preserve:

• full outer-box and vial photographs
• lot and expiry information
• supplier and invoice records
• the applicable label or IFU
• local authorization or conformity records
• storage and chain-of-custody information

Evidence and safety boundary

The reviewed Marllor brochure contains broad performance and tolerability claims, case images, treatment areas, and session examples. These are promotional or training claims and should not be converted into a universal protocol. The brochure does not substitute for an independently verified, current local label.

The FDA reports permanent scars, serious infections, skin deformities, cysts, and deep painful nodules after unapproved fat-dissolving injections as a category. Those reports are not product-specific incidence estimates for Aqualyx. They do show why authorization, authentic supply, sterile handling, anatomy, and adverse-event readiness cannot be inferred from the phrase “fat dissolver.”

Practitioner interpretation

For a patient or product record, Aqualyx alone is not enough. Record whether the package says Aqualyx Cosmetic or Aqualyx Face, the route represented in the applicable documentation, the market, lot, supplier, authenticity result, and exact authorization relied upon. Do not reconstruct a treatment recipe from promotional brochures or reseller instructions.

Nearby reference pages

• Fat-Reduction Injectables maps product identity, formulation, and regional authorization separately.
• Lipo Lab is a PPC/deoxycholate-associated commercial family with a different evidence and company-role problem.
• Kabelline is marketed as a deoxycholic-acid solution but lacks a publicly verified concentration and universal regulatory identity.